Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S237000
Reexamination Certificate
active
07981889
ABSTRACT:
Compounds of the formula (I):wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRXor CRXRY; if X═NRXthen n is 1 or 2 and if X═CRXRYthen n is 1; RXis selected from the group consisting of H, optionally substituted C1-20alkyl, C5-20aryl, C3-20heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RYis selected from H, hydroxy, amino; or RXand RYmay together form a spiro-C3-7cycloalkyl or heterocyclyl group; RC1and RC2are both hydrogen, or when X is CRXRY, RC1, RC2, RXand RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; and R1is selected from H and halo.
REFERENCES:
patent: 7449464 (2008-11-01), Martin et al.
patent: 7662818 (2010-02-01), Martin et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2006/0149059 (2006-07-01), Martin et al.
Vippagunta et al., “Crystalline solids”, Adv. Drug Delivery Reviews 48 (2001) 3-26.
Menear, et al., 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly (ADP-ribose) Polymerase-1; Journal of Medicinal Chemistry, XXXX, vol. xxx, No. xx; American Chemical Society, published on Web Sep. 19, 2008.
Bloch, et al. “Poly-adenosine diphosphate-ribose polymerase inhibition for myocardial protection: Pathophysiologic and physiologic considerations,”Journal of Thoracic and Cardiovascular Surgery, Year 2004; vol. 128; pp. 323-324.
Cockcroft, et al. “Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose) polymerase,”Bioorganic&Medicinal Chemistry Letters, Year Feb. 2006; vol. 16; Issue 4; pp. 1040-1044.
Cuzzocrea, “Shock, inflammation and PARP,”Pharmacological Research, Year Jul. 2005; vol. 52; Issue 1; pp. 72-82.
Loh, et al., “Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose) polymerase,”Bioorganic&Medicinal Chemistry Letters, Year May 2, 2005; vol. 15; Issue 9; pp. 2235-2238.
Miller, “Inhibition of TRPM2 function by PARP inhibitors protects cells from oxidative stress-induced death,”British Journal of Pharmacology, Year 2004; vol. 143; pp. 515-516.
Szabó, et al., “Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest,”Journal of Thoracic and Cardiovascular Surgery, Year 2003; vol. 126; pp. 651-658.
Tasatargil, et al., “Poly(ADP-Ribose) Polymerase Inhibition Prevents Homocysteine-Induced Endothelial Dysfunction in the Isolated Rat Aorta,”Pharmacology International Journal of Experimental and Clinical Pharmacology, Year 2004; vol. 72; pp. 99-105.
U.S. Appl. No. 10/876,080 Office Action, Jun. 23, 2005, 4 pages.
U.S. Appl. No. 10/876,080 Office Action, Nov. 21, 2005, 4 pages.
U.S. Appl. No. 10/876,080 Office Action, Feb. 22, 2006, 5 pages.
U.S. Appl. No. 10/876,080 Office Action, Jul. 12, 2006, 5 pages.
U.S. Appl. No. 10/876,080 Office Action—Final, Jan. 5, 2007, 5 pages.
U.S. Appl. No. 10/876,080 Office Action—Final, Oct. 4, 2007, 6 pages.
U.S. Appl. No. 11/318,155 Office Action, Mar. 17, 2008, 7 pages.
U.S. Appl. No. 11/318,155 Office Action, Jul. 11, 2008, 9 pages.
U.S. Appl. No. 11/318,155 Office Action—Final, Jan. 26, 2009, 8 pages.
Greene, T.W. et al., Protective Groups in Organic Synthesis, Chapters 2 and 7, John Wiley & Sons Inc. (1999) p. 17-23 and 494-503.
Jantzen et al., “B. Prodrugs,” taken from Modern Pharmaceutics, Third Edition, Banker and Rhodes, editors (1996) p. 596.
Vippagunta, S.R. et al., “Crystalline solids,” Adv. Drug Delivery Reviews (2001) 48:3-26.
Ashworth Alan
Barr Martin Niall Morrison
Cockcroft Xiao-Ling Fan
Jackson Stephen Philip
Kerrigan Frank
Finnegan Henderson Farabow Garrett & Dunner LLP
KuDos Pharmaceuticals Limited
Maybridge Limited
Ward Paul V.
Wilson James O.
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666249